Valeo Pharma commences commercial shipments of Redesca and Redesca HP across Canada

Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF) (FRA:VP2) said it has commenced commercial shipments across Canada of Redesca and Redesca HP, its low molecular weight heparin (LMWH) biosimilar.

LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. It has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

In a statement, Steve Saviuk, Valeo’s chief executive officer commented: “Making Redesca widely available in Canada is a key element of our commercialization plans and we are pleased to have done so ahead of target. We continue to work on expanding both public and private reimbursement coverage across all provinces.”

READ: Valeo Pharma enters into LOI with pan-Canadian Pharmaceutical Alliance over Redesca and Redesca HP to prevent and treat thromboembolic disorders

“Redesca is the first of three transformative products that Valeo is launching this year and it will be accretive to second-quarter revenues with increasing sales growth in the quarters to come,” Saviuk added.

Frederic Fasano, Valeo’s president and chief operating officer added: “Redesca is now available for patients, both at retail pharmacies and hospitals. The combination of a strong and proven safety profile, a complete
product line, a robust supply chain on top of material savings to payers, contributes to the compelling Redesca value proposition for patients, clinicians and healthcare systems.  We look forward to realizing Redesca’s full potential over the coming quarters”.

In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against coronavirus (COVID-10). The World Health Organization’s (WHO) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.

Valeo is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products.

Headquartered in Kirkland, Quebec, the company has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

Contact the author at [email protected]

Story by ProactiveInvestors